Merit Medical Launches the Ventrax™ Delivery System
Merit Medical Systems (NASDAQ: MMSI) has announced the US commercial launch of its Ventrax™ Delivery System, the latest addition to its electrophysiology and cardiac rhythm management portfolio. The system is designed to facilitate ablation procedures for treating ventricular tachycardia (VT), a condition contributing to approximately 75% of sudden cardiac deaths in the US.
The Ventrax system features a 95-cm sheath for targeted access, ultralow-profile transition between sheath and pigtail-dilator, and an angled tip to enhance ablation catheter reach. It provides retrograde aortic access, offering improved access to certain ventricle areas compared to traditional methods.
Key medical experts from Duke Health, including Dr. Albert Sun and Dr. Jason Koontz, contributed to the system's development. The device addresses a growing need in VT ablation procedures, which represent one of the fastest-growing areas in electrophysiology.
Merit Medical Systems (NASDAQ: MMSI) ha annunciato il lancio commerciale negli Stati Uniti del suo Ventrax™ Delivery System, l'ultima aggiunta al suo portafoglio di elettrofisiologia e gestione del ritmo cardiaco. Il sistema è progettato per facilitare le procedure di ablazione per il trattamento della tachicardia ventricolare (VT), una condizione che contribuisce a circa il 75% delle morti cardiache improvvise negli Stati Uniti.
Il sistema Ventrax è dotato di un guanto di 95 cm per un accesso mirato, una transizione ultracompatta tra il guanto e il dilatatore a coda di maiale, e una punta angolata per migliorare la portata del catetere di ablazione. Fornisce accesso aortico retrogrado, offrendo un accesso migliorato a determinate aree del ventricolo rispetto ai metodi tradizionali.
Esperti medici di spicco della Duke Health, tra cui il Dr. Albert Sun e il Dr. Jason Koontz, hanno contribuito allo sviluppo del sistema. Il dispositivo risponde a un'esigenza crescente nelle procedure di ablazione della VT, che rappresentano una delle aree in più rapida crescita nell'elettrofisiologia.
Merit Medical Systems (NASDAQ: MMSI) ha anunciado el lanzamiento comercial en EE. UU. de su Ventrax™ Delivery System, la última adición a su cartera de electrofisiología y manejo del ritmo cardíaco. El sistema está diseñado para facilitar los procedimientos de ablación para tratar la taquicardia ventricular (VT), una condición que contribuye a aproximadamente el 75% de las muertes cardíacas súbitas en EE. UU.
El sistema Ventrax cuenta con una funda de 95 cm para un acceso dirigido, una transición de perfil ultrabajo entre la funda y el dilatador en cola de cerdo, y una punta angulada para mejorar el alcance del catéter de ablación. Proporciona acceso aórtico retrógrado, ofreciendo un acceso mejorado a ciertas áreas del ventrículo en comparación con los métodos tradicionales.
Expertos médicos clave de Duke Health, incluidos el Dr. Albert Sun y el Dr. Jason Koontz, contribuyeron al desarrollo del sistema. El dispositivo aborda una necesidad creciente en los procedimientos de ablación de VT, que representan una de las áreas de más rápido crecimiento en electrofisiología.
Merit Medical Systems (NASDAQ: MMSI)는 자사의 Ventrax™ Delivery System의 미국 상업 출시를 발표했습니다. 이는 전기생리학 및 심장 리듬 관리 포트폴리오에 추가된 최신 제품입니다. 이 시스템은 심실 빈맥(VT) 치료를 위한 절제 절차를 용이하게 하도록 설계되었으며, VT는 미국에서 갑작스러운 심장 사망의 약 75%를 차지하는 상태입니다.
Ventrax 시스템은 목표 접근을 위한 95cm의 시스, 시스와 피그테일 확장기 사이의 초저프로파일 전환, 그리고 절제 카테터의 도달 범위를 향상시키기 위한 각도 팁을 특징으로 합니다. 이는 역행성 대동맥 접근을 제공하여 전통적인 방법에 비해 특정 심실 부위에 대한 접근성을 개선합니다.
듀크 헬스의 주요 의료 전문가인 알버트 선 박사와 제이슨 쿤츠 박사가 시스템 개발에 기여했습니다. 이 장치는 VT 절제 절차에서 증가하는 필요를 해결하며, 이는 전기생리학에서 가장 빠르게 성장하는 분야 중 하나입니다.
Merit Medical Systems (NASDAQ: MMSI) a annoncé le lancement commercial aux États-Unis de son Ventrax™ Delivery System, le dernier ajout à son portefeuille d'électrophysiologie et de gestion du rythme cardiaque. Le système est conçu pour faciliter les procédures d'ablation pour le traitement de la tachycardie ventriculaire (VT), une condition qui contribue à environ 75 % des morts cardiaques soudaines aux États-Unis.
Le système Ventrax dispose d'une gaine de 95 cm pour un accès ciblé, d'une transition ultra basse entre la gaine et le dilatateur en queue de cochon, et d'une pointe angulée pour améliorer la portée du cathéter d'ablation. Il offre un accès aortique rétrograde, permettant un meilleur accès à certaines zones du ventricule par rapport aux méthodes traditionnelles.
Des experts médicaux clés de Duke Health, y compris le Dr Albert Sun et le Dr Jason Koontz, ont contribué au développement du système. L'appareil répond à un besoin croissant dans les procédures d'ablation de VT, qui représentent l'un des domaines à la croissance la plus rapide en électrophysiologie.
Merit Medical Systems (NASDAQ: MMSI) hat die kommerzielle Einführung seines Ventrax™ Delivery Systems in den USA angekündigt, das neueste Produkt in seinem Portfolio für Elektrophysiologie und Herzrhythmusmanagement. Das System wurde entwickelt, um Ablationsverfahren zur Behandlung von ventrikulärer Tachykardie (VT) zu erleichtern, einer Erkrankung, die zu etwa 75 % der plötzlichen Herzinfarkte in den USA beiträgt.
Das Ventrax-System verfügt über eine 95 cm lange Hülle für gezielten Zugang, einen ultraflachen Übergang zwischen Hülle und Pigtail-Dilatator sowie eine gewinkelte Spitze zur Verbesserung der Reichweite des Ablationskatheters. Es bietet retrograden Zugang zur Aorta und ermöglicht einen verbesserten Zugang zu bestimmten Bereichen des Ventrikels im Vergleich zu herkömmlichen Methoden.
Wichtige medizinische Experten von Duke Health, darunter Dr. Albert Sun und Dr. Jason Koontz, haben zur Entwicklung des Systems beigetragen. Das Gerät erfüllt einen wachsenden Bedarf an VT-Ablationsverfahren, die zu den am schnellsten wachsenden Bereichen in der Elektrophysiologie gehören.
- Launch of innovative medical device in fast-growing VT ablation market
- Addresses significant medical need affecting 184,000-450,000 US deaths annually
- Product developed with input from leading medical experts
- Expands company's electrophysiology and cardiac rhythm management portfolio
- None.
Insights
Merit Medical's launch of the Ventrax™ Delivery System represents a strategic expansion in the high-growth electrophysiology (EP) segment. This novel device addresses a specific clinical challenge in ventricular tachycardia (VT) treatment—providing retrograde aortic access to reach areas of the heart that are difficult to access through traditional methods.
The timing is particularly advantageous as VT ablation is described as one of the fastest growing areas in electrophysiology. This positions Merit to capture market share in a segment with significant growth potential. The Ventrax system joins Merit's existing cardiac intervention portfolio that includes HeartSpan®, Worley™, and other product lines, strengthening their competitive position.
From a technical perspective, the system's 95-cm sheath with ultralow-profile transition and angled tip appears to address genuine clinical needs, with endorsements from Duke Health electrophysiologists validating its utility. The market opportunity is substantial—ventricular arrhythmias reportedly cause approximately 75% of sudden cardiac deaths, resulting in an estimated 184,000-450,000 deaths annually in the US alone.
While revenue impact isn't quantified, this launch aligns with Merit's focus on specialized medical devices with higher margins. For a company with approximately 7,000 employees and a global sales force, having differentiated products in growing segments is crucial for maintaining competitive advantages in the medical device marketplace.
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia
SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System.
The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac interventions, including the HeartSpan®, Worley™, Prelude SNAP™, and SafeGuard Focus® product lines.
Ventrax is intended to facilitate placement of devices used in ablation procedures commonly performed to treat an abnormally fast heartbeat known as ventricular tachycardia (VT). Ventricular arrhythmias, which include VT, are believed to cause approximately three out of four sudden cardiac deaths, which result in an estimated 184,000–450,000 lives lost in the United States each year.¹
The all-in-one device provides a streamlined pathway for ablation catheters to enter the left ventricle through the aorta, an approach known as retrograde aortic access.
“For the electrophysiologist, using retrograde aortic access was always a risk-benefit decision, and the community has needed a tool that would make that decision easier,” said Albert Sun, MD, electrophysiologist at Duke Health in Durham, NC, and whose advice was instrumental in Merit's development of the Ventrax system.
Retrograde aortic access can be useful to reach certain areas of the ventricle compared to traditional methods, such as transseptal puncture. Using this approach, these areas of the left ventricle are more accessible,² supporting targeted treatment.
“The new retrograde delivery system provides access to the left ventricle, allowing for the exchange of catheters to diagnose, map, or treat VT,” said Jason Koontz, MD, PhD, electrophysiologist at Duke Health and product development consultant to Merit. “This adds to our tools as we work to deliver the best possible outcomes for our patients.”
Learn more about the Ventrax Delivery System
Key features of the Ventrax Delivery System include a 95-cm sheath designed to access desired target locations. An ultralow-profile transition between its sheath and pigtail-dilator offers smooth insertion, and an angled tip enhances the reach of an ablation catheter.
VT ablation is one of the fastest growing areas in electrophysiology. Many physicians are using retrograde aortic access for VT procedures, and researchers are increasingly investigating the technique.
“Effective access is essential to supporting the growth of VT ablation,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “We are proud to take another significant step toward providing electrophysiologists with a valuable tool that helps fill this need in patient care.”
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
- Khurshid et al. 2018. “Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults.” Circ Arrhythm Electrophysiol 11 (7): e006273. (PMID: 29954742)
- Adlan et al. 2019. “Retrograde Aortic Access During Ventricular Tachycardia Ablation: Indications, Techniques, and Challenges.” Journal of Cardiovascular Electrophysiology 30 (11): 2629–2639. (PMID: 31502368)
FAQ
What is the purpose of Merit Medical's new Ventrax Delivery System (MMSI)?
What are the key features of Merit Medical's Ventrax Delivery System (MMSI)?
How does the Ventrax system address ventricular tachycardia treatment needs?
What market opportunity does the Ventrax system target for Merit Medical (MMSI)?
